Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 129, Issue 7
February 16 2017
Issue Cover

Table of Contents

INSIDE BLOOD COMMENTARIES

INSIDE BLOOD COMMENTARY
Stopping second-generation TKIs in CML
Clinical Trials & Observations
Pierre Laneuville
View Articletitled, Stopping second-generation TKIs in CML
INSIDE BLOOD COMMENTARY
iNKT cell defects in HHV-8–associated MCD
Thomas S. Uldrick
View Articletitled, iNKT cell defects in HHV-8–associated MCD
INSIDE BLOOD COMMENTARY
Opana ER–induced thrombotic microangiopathy
Bernhard Lämmle
View Articletitled, Opana ER–induced thrombotic microangiopathy

PERSPECTIVE

Myeloid malignancies and the microenvironment
CME
Claudia Korn,Simón Méndez-Ferrer
View Articletitled, Myeloid malignancies and the microenvironment

REVIEW ARTICLE

Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target
Michael T. Werner,Chen Zhao,Qian Zhang,Mariusz A. Wasik
View Articletitled, Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target

EVIDENCE-BASED FOCUSED REVIEW

Does ruxolitinib prolong the survival of patients with myelofibrosis?
Clinical Trials & Observations
Francisco Cervantes,Arturo Pereira
View Articletitled, Does ruxolitinib prolong the survival of patients with myelofibrosis?

HOW I TREAT

How I treat atypical chronic myeloid leukemia
Clinical Trials & Observations
Jason Gotlib
View Articletitled, How I treat atypical chronic myeloid leukemia

CLINICAL TRIALS AND OBSERVATIONS

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
Clinical Trials & Observations
Delphine Rea,Franck E. Nicolini,Michel Tulliez,François Guilhot,Joelle Guilhot,Agnès Guerci-Bresler,Martine Gardembas,Valérie Coiteux,Gaelle Guillerm,Laurence Legros,Gabriel Etienne,Jean-Michel Pignon,Bruno Villemagne,Martine Escoffre-Barbe,Jean-Christophe Ianotto,Aude Charbonnier,Hyacinthe Johnson-Ansah,Marie-Pierre Noel,Philippe Rousselot,François-Xavier Mahon,for the France Intergroupe des Leucémies Myéloïdes Chroniques
View Articletitled, Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

IMMUNOBIOLOGY

iNKT and memory B-cell alterations in HHV-8 multicentric Castleman disease
Zineb Sbihi,Antoine Dossier,David Boutboul,Lionel Galicier,Christophe Parizot,Amandine Emarre,Bénédicte Hoareau,Nicolas Dupin,Anne-Geneviève Marcelin,Anne Oudin,Claire Fieschi,Félix Agbalika,Brigitte Autran,Eric Oksenhendler,Guislaine Carcelain
View Articletitled, iNKT and memory B-cell alterations in HHV-8 multicentric Castleman disease
Supplemental data

LYMPHOID NEOPLASIA

EBI2 overexpression in mice leads to B1 B-cell expansion and chronic lymphocytic leukemia–like B-cell malignancies
Kristine Niss Arfelt,Line Barington,Tau Benned-Jensen,Valentina Kubale,Alexander L. Kovalchuk,Viktorija Daugvilaite,Jan Pravsgaard Christensen,Allan Randrup Thomsen,Kristoffer L. Egerod,Maria R. Bassi,Katja Spiess,Thue W. Schwartz,Hongsheng Wang,Herbert C. Morse, III,Peter J. Holst,Mette M. Rosenkilde
View Articletitled, EBI2 overexpression in mice leads to B1 B-cell expansion and chronic lymphocytic leukemia–like B-cell malignancies
Supplemental data

MYELOID NEOPLASIA

Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations
Clinical Trials & Observations Brief Report
Thierry M. Nordmann,Freimut D. Juengling,Mike Recher,Christoph T. Berger,Daniel Kalbermatten,Andreas Wicki,Aino Paasinen-Sohns,Gieri Cathomas,Alexandar Tzankov,Thomas Daikeler
View Articletitled, Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both <em>BRAF</em> and <em>KRAS</em> mutations
Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia
e-blood
Ying Qu,Lee Siggens,Lina Cordeddu,Verena I. Gaidzik,Kasper Karlsson,Lars Bullinger,Konstanze Döhner,Karl Ekwall,Sören Lehmann,Andreas Lennartsson
View Articletitled, Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia
Supplemental data

PLATELETS AND THROMBOPOIESIS

A novel mechanism regulating human platelet activation by MMP-2–mediated PAR1 biased signaling
Manuela Sebastiano,Stefania Momi,Emanuela Falcinelli,Loredana Bury,Marc F. Hoylaerts,Paolo Gresele
View Articletitled, A novel mechanism regulating human platelet activation by MMP-2–mediated PAR1 biased signaling
Supplemental data

THROMBOSIS AND HEMOSTASIS

A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER
Ryan Hunt,Ayla Yalamanoglu,James Tumlin,Tal Schiller,Jin Hyen Baek,Andrew Wu,Agnes B. Fogo,Haichun Yang,Edward Wong,Peter Miller,Paul W. Buehler,Chava Kimchi-Sarfaty
View Articletitled, A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER
Supplemental data

TRANSPLANTATION

Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis
Clinical Trials & Observations
Ryan H. Moy,Austin P. Huffman,Lee P. Richman,Lisa Crisalli,Ximi K. Wang,James A. Hoxie,Rosemarie Mick,Stephen G. Emerson,Yi Zhang,Robert H. Vonderheide,David L. Porter,Ran Reshef
View Articletitled, Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis
Supplemental data

BLOOD WORK

Kikuchi-Fujimoto disease
Branko Cuglievan,Roberto N. Miranda
View Articletitled, Kikuchi-Fujimoto disease
Myelodysplastic syndrome with excess blasts-2 associated with erythroid predominance
Maryam Pourabdollah,Hong Chang
View Articletitled, Myelodysplastic syndrome with excess blasts-2 associated with erythroid predominance

ERRATUM

Sanada C, Xavier-Ferrucio J, Lu Y-C, et al. Adult human megakaryocyte-erythroid progenitors are in the CD34+CD38mid fraction. Blood. 2016;128(7):923-933.
View Articletitled, Sanada C, Xavier-Ferrucio J, Lu Y-C, et al. Adult human megakaryocyte-erythroid progenitors are in the CD34<sup>+</sup>CD38<sup>mid</sup> fraction. <em>Blood.</em> 2016;128(7):923-933.

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS

The microenvironment in myeloid malignancies
CME
View Articletitled, The microenvironment in myeloid malignancies
All Issues

Advertisement intended for health care professionals

Licking the wound with procoagulant vesicles
Approaching Hypercalcemia in Monoclonal Gammopathy of Undetermined Significance: Insights from the iStopMM study
CAR T-cells in autoimmunity: game changer or stepping stone?
Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH
How I treat quantitative fibrinogen disorders

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals